20 results about "Enhancing Antibodies" patented technology

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

Disclosed herein are cells (e.g, immune cells such as T cells) engineered to contain and / or express a Lysis Sensor Receptors (LSR) comprising an extracellular domain with affinity and specificity for an intracellular product of a diseased cell such as a cancer cell; a transmembrane element and at least one signaling element, and a chimeric antigen receptor (CAR) comprising an extracellular domain with affinity and specificity for an extracellular product of a diseased cell such as a cancer cell; a transmembrane element and at least one signaling element. Also provided herein are various uses of such engineered cells, including in the treatment of cancer, for example to enhance T cell activity (e.g, TIL and / or CAR-T cell activity) and / or to enhance antibody-based therapy, such as cancer immunotherapy.

The present invention relates to the identification of key residues within mouse IgG3 antibodies (mAbs) that are responsible for intermolecular cooperativity and their transfer into IgG1 antibodies in order to enhance their functional affinity and direct a cell killing.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The invention provides a preparation method of an antibody conjugate containing an sLeX tetrasaccharide structure, which comprises the following steps: S1, sequentially adding Endo S2 enzyme and alpha-L-fucosidase into a target antibody, and respectively analyzing glycosylation to avoid modification site conflict or carbohydrate chain structure interference; s2, adding the accurately represented antibody in the S1, B4GalT1 and UDP-Gal into a Tris-HCl system containing Mn < 2 + >, and incubating to obtain a reaction solution I; s3, the reaction liquid I, ST3Gal3, CMP-Neu5Ac and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is carried out; adding CMP-N-acyl neuraminic acid phosphodiesterase for reaction, and purifying Protein A to obtain a purified antibody I; s4, the purified antibody I, alpha1, 3 FucT-2HR, GDP-Fuc and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is performed; and purifying Protein A to obtain a target product. According to the modified antibody obtained by the invention, while the targeting property is improved, the binding affinity of the antibody and a tumor cell surface antigen can be enhanced, so that the immune blocking activity of the antibody is further enhanced, and dual improvement of the targeting property and the activity is realized.

The invention belongs to the technical field of biological medicine, and particularly relates to a macrophage bionic vesicle nano preparation as well as a preparation method and application thereof. The invention provides a macrophage bionic vesicle nano preparation, which is characterized in that a tumor targeting peptide is used for modifying a macrophage bionic vesicle, and a targeting NSUN family methyltransferase siRNA (small interfering Ribonucleic Acid) is wrapped. The macrophage bionic vesicles modified by the tumor targeting peptide have good gastric cancer cell targeting property, the NSUN expression level of gastric cancer cells can be inhibited by wrapping targeted NSUN family methyltransferase siRNA, the abnormal modification level of gastric cancer m5C is reduced, and the effect of enhancing the treatment of the gastric cancer by the PD-1 antibody is achieved. The results of the embodiment show that the macrophage bionic vesicle nano preparation provided by the invention acts on gastric cancer cells, and can specifically target the gastric cancer cells, induce ferroptosis of the gastric cancer cells, improve the curative effect of a PD-1 antibody, prolong the survival time of mice and improve the tumor immune microenvironment.

The present invention provides a covalent conjugate. The conjugate includes an antibody or antibody derivative, at least two LL37-derived polypeptides, and a payload. The antibody or antibody derivative targets a cell that has phosphatidylserine in its outer leaflet. The payload includes: a small molecule cytotoxic drug of less than 3 kDa, or a plurality thereof; or a peptide or protein of less than 100 kDa. Uses and methods of using these covalent conjugates are also provided, related to enhancing delivery of the antibody / derivative or the payload, e.g. to enhance therapeutic or diagnostic effectiveness.

This invention relates to improving cancer treatment methods using PD-1 / PD-L1 antibodies. In particular, this invention is based on the finding that patients with a TGFβ-specific T cell response are likely to show favorable outcomes in cancer treatment with PD-1 / PD-L1 antibodies. Therefore, this invention provides treatment for such patient groups with PD-1 / PD-L1 antibodies and actively promotes the TGFβ-specific T cell response in order to enhance the therapeutic effect of PD-1 / PD-L1 antibodies.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.

The application discloses a method for modifying pH sensitivity of an antibody based on yeast display. A degenerate codon VAM (coding H, E, D, K, N, Q) is used to construct a yeast display library for at least two region combinations in LCDR1, HCDR1 and HCDR3, and 1-2 mutations are introduced into each CDR region, taking the antibody to be modified as a template. The library is transformed into Saccharomyces cerevisiae EBY100 to induce expression, and fast dissociation clones are enriched through four rounds of flow sorting (including pH 7.4 binding, pH 6.0 non-binding and'saturated binding-acid dissociation-neutral re-binding' screening). The obtained antibody has a KD ratio at pH 5.8 to pH 7.4 of up to 674.46, an expression amount of up to 263.3 mg / L, excellent physicochemical properties, and can enhance the curative effect of antibody conjugated drugs and improve the therapeutic index.

This invention belongs to the field of biology and discloses a VHH antibody against human FcRn and its applications. The complementarity-determining regions (CDR1-CDR3) of the VHH antibody are shown in SEQ ID NO. 1-9. Some examples of the anti-human FcRn VHH antibodies of this invention can specifically bind to human FcRn; they can replace traditional antibodies and be used in the treatment and diagnosis of autoimmune diseases; the fused Fc fragment targets and binds to the FcRn receptor, effectively reducing the half-life of IgG in the blood while enhancing antibody targeting. Some examples of the anti-human FcRn VHH antibodies of this invention, by fusing the Fc fragment, can increase their affinity for the FcRn receptor, effectively reducing the half-life of IgG in autoimmune diseases, while also mitigating ADCC and CDC effects.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

Amino acid sequences capable of enhancing nuclear translocation are provided. Also referred to a nuclear localization signals (NLS) the sequences can be linked to or grafted into antibodies or fragments or fusion proteins thereof to enhance nuclear translocation of the antibody. Compositions and antibodies including an NLS conjugated or otherwise linked directly or indirectly to an active agent cargo are also provided. Exemplary cargo includes proteins, peptides, carbohydrates, polysaccharides, nucleic acid molecules, inorganic molecules, organic molecules, and diagnostic agents. Pharmaceutical compositions further including a pharmaceutically acceptable carrier are also provided. Methods of delivering the composition or antibody alone or with a cargo linked thereto to the nucleus of cell, methods of selecting or screening for compositions having a desired cellular activity, and methods of treating diseases and disorders are also provided.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as "RE mutations") per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody¬ dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

Provided herein is a method for producing an antibody with improved productivity while maintaining its titer by causing at least one hydroxyamino acid contained in the light chain of the antibody to undergo O-linked glycosylation. Also provided is an antibody so produced.

The invention provides a model training method, a nanometer antibody inverse folding method and electronic equipment. The model training method comprises the following steps: performing molecular dynamics simulation on an original antibody structure sample to obtain a molecular dynamics track of the original antibody structure sample; extracting a plurality of enhanced antibody structure samples from the molecular dynamics trajectory so as to form an enhanced data set; processing each enhanced antibody structure sample in the enhanced data set by using a machine learning model to obtain a predicted amino acid sequence of each enhanced antibody structure sample; determining a loss function according to the predicted amino acid sequence of each enhanced antibody structure sample; and training the machine learning model by using the loss function to obtain a sequence prediction model. The trained sequence prediction model is used for carrying out nano antibody inverse folding treatment, and a more accurate prediction result can be obtained.

An object of the present application is to provide an anti-VEGF-A antibody and an antibody conjugate thereof.SOLUTION: Anti-VEGF-A antibodies and antibody conjugates thereof have been discovered, and it has been discovered that some embodiments of the antibodies can be conjugated to moieties such as HEMA-PC polymers, that some embodiments of the antibody conjugates can retain or enhance antibody activity, and that the antibodies and antibody conjugates can be particularly useful for the treatment of diabetic retinopathy. Furthermore, a method for conjugating polymers to proteins, e.g. antibodies such as IgG1, has been found.SELECTED DRAWING: Figure 1

Antibodies having enhanced biodistribution and / or pharmacokinetics obtained through conjugation of a negatively charged organic moiety are provided. Also provided are methods of enhancing the biodistribution and / or pharmacokinetics of an antibody. The enhanced antibodies find use in immunotherapy, radiotherapy, and in vivo imaging.

Embodiments of the present disclosure include apparatus, systems and methods related to sample analysis. Particular embodiments include a microfluidic electrochemical immunosensor that employ a unique finger-actuated mixer for rapid, ultrasensitive measurements of protein biomarkers. This mixer generates swirling microflows in the liquid sample, which accelerates biomolecular transport, enhances antibody-antigen reactions and promotes immunocomplex formation. In specific embodiments, mixing can be implemented during the incubation steps, which accelerates biomolecular transport and promotes immunocomplex formation, leading to enhanced analytical sensitivity and a shortened detection time.